Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

BIVI stock hub

BioVie Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BIVIis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

11.1M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BIVI

In the news

Latest news · BIVI

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-80.7

P25 -106.6P50 -46.9P75 -3.1

ROIC-51.8

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BIVI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

173

Groups with data

Currency

USD

Showing 173 of 173 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001580149
Company name	BioVie Inc.
Country	United States
Country code	US
Cusip	09074F504
Employees	13
Employees Change	-1%
Employees Change Percent	-7.14
Enterprise value	$-9.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US09074F5044
Last refreshed	2026-05-10
Market cap	$11.1M
Market cap category	Nano-Cap
Price	$1.47
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	BIVI
Website	https://bioviepharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-157.68%
P/B ratio	0.58x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-17.5M
Net Income Growth Quarters	1%
Net Income Growth Years	2%
Profit Per Employee	$-1.3M
ROA	-47.2
Roa5y	-493.9
ROCE	-93.34
ROE	-80.74
ROIC	-51.84

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-51.97%
Cagr1y	-86.41%
Cagr3y	-87.83%
Cagr5y	-75.1%
EPS Growth Quarters	11
EPS Growth Years	2
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$22.5M
Cash	$20.5M
Current Assets	$21.8M
Current Liabilities	$3M
Debt	$314,915
Debt Equity	$0.02
Equity	$19.3M
Interest Coverage	-1,013.8
Liabilities	$3.2M
Long Term Assets	$711,859
Long Term Liabilities	$232,517
Net Cash	$20.2M
Net Cash By Market Cap	$182
Net Cash Growth	-15.81%
Net Debt Equity	$-1.05
Tangible Book Value	$18.9M
Tangible Book Value Per Share	$2.5
WACC	8.12

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.25
Net Working Capital	$-1.7M
Quick ratio	6.9
Working Capital	$18.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-415.78%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.93%
1Y total return	-86.39%
200-day SMA	1.76
3Y total return	-99.82%
50-day SMA	1.45
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.9%
All Time High	6,875
All Time High Change	-99.98%
All Time High Date	2014-07-17
All Time Low	1.06
All Time Low Change	38.68%
All Time Low Date	2026-02-05
ATR	0.11
Beta	0.72
Beta1y	0.25
Beta2y	1.83
Ch YTD	26.72
High	1.56
High52	12.4
High52 Date	2025-05-08
High52ch	-88.15%
Low	1.42
Low52	1.06
Low52 Date	2026-02-05
Low52ch	38.68%
Ma50ch	1.31%
Premarket Change Percent	7.77
Premarket Price	$1.66
Premarket Volume	1,403
Price vs 200-day SMA	-16.48%
RSI	45.8
RSI Monthly	37.45
RSI Weekly	39.13
Sharpe ratio	-1.59x
Sortino ratio	-1.85
Total Return	-415.78%
Tr YTD	26.72
Tr1m	2.08%
Tr1w	-12.5%
Tr3m	30.09%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$-0.73
Operating Income	$-18.2M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	7,500,849%
Float Percent	99.47%
Net Borrowing	2,901,341
Shares Insiders	0.53%
Shares Institutions	15.51%
Shares Out	7,540,734
Shares Qo Q	51.9%
Shares Yo Y	415.78%
Short Float	1.72%
Short Ratio	2.01
Short Shares	1.71

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	99,546.9x
Bv Per Share	2.55
Ch10y	-99.93
Ch1m	2.08
Ch1w	-12.5
Ch1y	-86.39
Ch3m	30.09
Ch3y	-99.82
Ch5y	-99.9
Ch6m	-0.68
Change	-4.55%
Change From Open	-4.55
Close	1.54
Days Gap	0
Depreciation Amortization	229,377
Dollar Volume	163,264.1
Earnings Date	2026-05-11
Earnings Time	amc
EBIT	$-18.2M
EBITDA	$-18M
EPS	$-4.15
F Score	1
Financing CF	10,457,629
Fiscal Year End	June
Founded	2,013
Goodwill	345,711
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-02-06
Last Report Date	2025-12-31
Last Split Date	2025-07-07
Last Split Type	Reverse
Last10k Filing Date	2025-08-15
Ma150	1.46
Ma150ch	0.96%
Ma20	1.55
Ma20ch	-5.28%
Net CF	-3,864,932
Next Earnings Date	2026-05-22
Open	1.54
Optionable	No
Position In Range	35.11
Post Close	1.47
Postmarket Change Percent	2.04
Postmarket Price	$1.5
Ppne	302,495
Pre Close	1.54
Price Date	2026-05-08
Ptbv Ratio	0.59
Relative Volume	1.12x
Share Based Comp	2,319,417
Tr6m	-0.68%
Us State	Nevada
Volume	111,064

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BIVI pay a dividend?

Capital-return profile for this ticker.

Performance

BIVI stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BIVI?

Insider, institutional, and short-interest positioning.

Institutional ownership

+15.5%

Float: +99.5% of shares outstanding

Insider ownership

+0.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BIVI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

45.8

Neutral momentum band

Price vs 200-day MA

-16.5%

50/200-day relationship not available

Beta (5Y)

0.72

Less volatile than the market

Sharpe ratio

-1.59

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BIVI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BIVI stock rating?

BioVie Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BIVI analysis?

The full report lives at /stocks/BIVI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BIVI?

The latest report frames BIVI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BIVI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.